SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against CytRx Corporation and Certain Officers - CYTR
PR Newswire - Fri May 09, 5:15PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation ("CytRx" or the "Company"
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in CytRx Corporation to Contact Brower Piven Before the May 13, 2014 Lead Plaintiff Deadline -- CYTR
GlobeNewswire - Thu May 08, 10:45AM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation ("CytRx" or the "Company"
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against CYTRX CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- CYTR
GlobeNewswire - Tue May 06, 12:02PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased CytRx Corporation ("CytRx" or the "Company"
Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline in CytRx Securities Fraud Class Action
PR Newswire - Tue May 06, 11:26AM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) ("CytRx" or "the Company"
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against CytRx Corporation
Business Wire - Tue May 06, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of CytRx Corporation ("CytRx" or the "Company"
CytRx Reports Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data in Second-Line Soft Tissue Sarcoma
Business Wire - Mon May 05, 5:00AM CDT
--Median Overall Survival Data Support the Ongoing Clinical Development of Aldoxorubicin in Soft Tissue Sarcoma
Pre-Market Review on Top Gainers -- Research on SouFun Holdings, CytRx, Iridium Communications, and Qihoo 360 Technology
PR Newswire - Fri May 02, 7:12AM CDT
The US markets finished on a mixed note on Thursday, May 01, 2014, with the NASDAQ Composite closing at 4,127.45, up 0.31%, the Dow Jones Industrial Average ending the session at 16,558.87, down 0.13% and the S&P 500 finishing 0.01% lower at 1,883.68. During the trading session, five out of ten sectors finished on a positive note. A number of stocks saw large movements, including SouFun Holdings Ltd (NYSE: SFUN), CytRx Corp. (NASDAQ: CYTR), Iridium Communications Inc. (NASDAQ: IRDM) and Qihoo 360 Technology Co. Ltd (NYSE: QIHU). Free technical research on SFUN, CYTR, IRDM and QIHU can be downloaded upon signing up at:
CYTRX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CytRx Corporation - CYTR
GlobeNewswire - Thu May 01, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF"
Stock to Watch: CytRx Up 16.3% (CYTR)
Comtex SmarTrend(R) - Thu May 01, 10:41AM CDT
CytRx (NASDAQ:CYTR) is one of today's best performing low-priced stocks, up 16.3% to $3.57 on 1.1x average daily volume. CytRx has traded 2.4 million shares thus far today, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (16.3% to the Dow's -0.0%) and outperformed the S&P 500 (16.3% to the S&P's 0.1%) during today's trading.
CytRx Reports 2014 First Quarter Financial Results
Business Wire - Thu May 01, 5:01AM CDT
--Global Phase 2b Clinical Trial of Aldoxorubicin Selected for ASCO 2014 Oral Presentation
CytRx to Present Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data in Second-Line Soft Tissue Sarcoma at Upcoming Research and Development Day
Business Wire - Mon Apr 28, 5:01AM CDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will be presenting updated progression-free survival and overall survival results from its completed Phase 1b/2 clinical trial of aldoxorubicin in soft tissue sarcoma. The trial was conducted at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial's principal investigator, Dr. Sant Chawla, will present the data at CytRx's Research and Development Day which is taking place on Friday, May 2, from 8:30 - 11:30 am EDT at the Harvard Club in New York City.
EQUITY ALERT: Rosen Law Firm Reminds CytRx Corporation Investors of Important May 14, 2014 Deadline in the Class Action Filed by the Firm -- CYTR
GlobeNewswire - Sat Apr 26, 8:51PM CDT
The Rosen Law Firm reminds all purchasers of the common stock of CytRx Corporation (Nasdaq:CYTR) between November 22, 2013, and March 13, 2014, including the CYTR's public offering completed on or before February 5, 2014, of the important May 14, 2014 lead plaintiff deadline.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in CytRx Corporation of Class Action Lawsuit and Upcoming Deadline -- CYTR
GlobeNewswire - Fri Apr 25, 3:49PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation ("CytRx" or the "Company"
CytRx Announces Global Phase 2b Trial of Aldoxorubicin in Soft Tissue Sarcomas Selected for Oral Presentation at the 2014 ASCO Annual Meeting
Business Wire - Thu Apr 24, 6:01AM CDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin, its lead product candidate, versus doxorubicin in patients with advanced soft tissue sarcomas (STS) has been selected for oral presentation at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place May 30 - June 3 in Chicago.
Lieff Cabraser Reminds CytRx Corporation Investors of Upcoming Deadline in Class Action Litigation - CYTR
Business Wire - Wed Apr 23, 8:01AM CDT
Lieff, Cabraser, Heimann & Bernstein, LLP reminds investors of the May 14, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or acquired the securities of CytRx Corporation ("CytRx" or the "Company"
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in CytRx Corporation to Contact Brower Piven Before the May 13, 2014 Lead Plaintiff Deadline
Business Wire - Tue Apr 15, 9:00PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation ("CytRx" or the "Company"
Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors of the May 13, 2014 Deadline to File for Lead Plaintiff in the Securities Fraud Class Action Against CytRx Corporation -- CYTR
GlobeNewswire - Tue Apr 15, 3:15PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP reminds investors of the May 13, 2014 deadline to file for lead plaintiff in the securities fraud class action against CytRx Corporation (Nasdaq:CYTR) ("CytRx" or "the Company"
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against CytRx Corporation
Business Wire - Thu Apr 10, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of CytRx Corporation ("CytRx" or the "Company"